Sangamo Therapeutics, Inc
isaralgagene civaparvovec
Fabry disease
Resolved
453days ago
Phase 2 readout Β· Apr 10, 2025
What's at stake
Phase 2 trial results for isaralgagene civaparvovec in Fabry disease are due Apr 10, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
Β· SEC 8-K
verified 15h ago
ββ¦ Durability of effect was demonstrated with elevated expression of alpha-galactosidase A (Ξ±-Gal A) activity maintained for up to 4.5 years for the longest treated patient, alongside statistically significant Quality of Life improvements anβ